Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
BioAtla, Inc. is a clinical-stage biopharmaceutical company specializing in conditionally active biologics (CABs), a novel class of antibody-based therapeutics targeting solid tumor cancers. Its proprietary CAB technology exploits tumor microenvironment acidity to selectively bind cancer cells, reducing off-tumor toxicity. BioAtla develops monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, and CAR-T therapies, focusing on improving cancer treatment efficacy and safety through enhanced tumor specificity.
This description was generated via AI from an annual report. Updated about 1 year ago.